If You Invested in Regen Biopharma (RGBPP)

Regen BioPharma, Inc. – Preferred Stock Series A (RGBPP) represents a class of equity in Regen BioPharma, Inc., a publicly traded biotechnology company listed on the OTC Pink marketplace under the symbols RGBP and RGBPP. The company operates in the pharmaceutical preparation manufacturing space within the broader manufacturing sector and focuses on immunology and immunotherapy.

According to company disclosures, Regen BioPharma is advancing a diverse pre-clinical pipeline that spans cell therapies, RNA vaccines, RNA and DNA therapeutics, and small molecule drugs. The firm states that it is focused on rapidly moving novel technologies through pre-clinical and Phase I/II clinical trials, with an emphasis on treatments for cancer and autoimmune disorders.

Core therapeutic focus

A central program highlighted by Regen BioPharma is HemaXellerate, described as a stem cell-derived, cell-based therapeutic. The company reports that HemaXellerate has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance and that it is preparing or planning a Phase I clinical trial. HemaXellerate is designed to stimulate bone marrow regeneration following injury caused by autoimmune conditions, chemotherapy, or radiation, and to restore the body’s ability to generate healthy blood cells.

Regen BioPharma has stated that its initial clinical focus for HemaXellerate is aplastic anemia, a rare and potentially life‑threatening bone marrow disorder characterized by insufficient blood cell production. The company has submitted an Orphan Drug Application (ODA) to the FDA for HemaXellerate in this indication and has discussed responding to FDA comments on that application. It has also indicated that HemaXellerate is an autologous mesenchymal stem cell product intended to restore hematopoietic stem cell function and reverse bone marrow suppression associated with aplastic anemia.

Expanded applications and oncology supportive care

Beyond aplastic anemia, Regen BioPharma has publicly discussed exploring chemotherapy‑induced bone marrow suppression (myelosuppression) as an additional indication for HemaXellerate. Company communications describe myelosuppression as a serious complication of cytotoxic chemotherapy that can lead to anemia, neutropenia, and thrombocytopenia, with downstream risks such as fatigue, infection, and bleeding. Regen BioPharma characterizes current standard-of-care options in this setting as largely symptomatic and focused on individual blood cell lineages.

In contrast, the company describes HemaXellerate as a multi‑lineage regenerative approach designed to stimulate the body’s own hematopoietic stem cells and enhance recovery of erythrocytes, leukocytes, and platelets. Regen BioPharma has indicated that it is evaluating early‑phase clinical development in chemotherapy patients as a potential second indication after aplastic anemia.

Pipeline and technology areas

In addition to HemaXellerate, Regen BioPharma states that it is active in several other technology areas within immunology and immunotherapy. Public descriptions of the company reference:

• Cell therapies, including programs such as DuraCAR mentioned in investor presentations.
• RNA vaccines, which the company lists as part of its pre‑clinical pipeline.
• RNA and DNA therapeutics, reflecting a focus on nucleic acid‑based approaches to modulating immune and disease pathways.
• Small molecule drugs targeting cancer and autoimmune disorders.

The company positions these programs as being at the pre‑clinical or early clinical stage, with an emphasis on progressing them through Phase I/II trials.

Regulatory and clinical development approach

Regen BioPharma has highlighted several regulatory and development milestones around HemaXellerate. It reports FDA IND clearance to initiate a Phase I clinical trial in aplastic anemia and has described the program as "clinical study‑ready" or poised to move into Phase I. The company has also communicated its intention to pursue Orphan Drug Designation for HemaXellerate in aplastic anemia and has submitted an Orphan Drug Application to the FDA.

In its public statements, Regen BioPharma notes that Orphan Drug Designation can provide incentives such as tax credits for qualified clinical testing expenses, potential marketing exclusivity for a defined period upon approval, and certain fee exemptions. The company links these incentives to its strategy for advancing therapies in rare diseases with high unmet medical need.

To support clinical execution, Regen BioPharma reports collaborating with a clinical research organization (CRO) experienced in complex trials. It has discussed expected timelines for completion of the planned Phase I trial once initiated, while emphasizing that HemaXellerate is its most advanced asset.

Capital markets and corporate structure

Regen BioPharma, Inc. is incorporated in Nevada, as disclosed in its SEC filings, and has a Commission File Number of 333‑191725. The company files periodic and current reports with the U.S. Securities and Exchange Commission. Recent Form 8‑K filings describe unregistered sales of equity securities under Regulation A and Section 4(a)(2) of the Securities Act of 1933, including Tier 2 Regulation A offerings. These filings indicate that shares were sold directly through company management without underwriters or commissions, with certain proceeds designated for working capital and some issuances used to satisfy principal and accrued interest on convertible indebtedness.

The RGBPP preferred stock is associated with this broader capital structure. While specific terms of the preferred series are not detailed in the provided materials, investors in RGBPP are gaining exposure to the same underlying biotechnology business, including its immunology and immunotherapy programs and the HemaXellerate platform.

Industry context based on company statements

Within the pharmaceutical preparation manufacturing industry, Regen BioPharma describes itself as focused on regenerative and immune‑based therapies for serious conditions such as cancer, autoimmune disorders, and hematologic diseases. Its communications emphasize rare diseases like aplastic anemia, where treatment options are limited, and supportive oncology care settings such as chemotherapy‑induced bone marrow suppression.

According to the company, these areas represent markets with high unmet medical need and, in some cases, significant commercial potential. Regen BioPharma links its scientific programs to these needs by highlighting mechanisms such as bone marrow regeneration, restoration of hematopoietic function, and modulation of immune responses through cell‑based, RNA, DNA, and small‑molecule approaches.

Engagement with the investment community

Regen BioPharma regularly participates in Emerging Growth Conference events, where it presents updates on HemaXellerate, its broader pipeline, and corporate goals. These events are described as interactive online presentations that allow shareholders, analysts, and other investors to ask questions in real time. The company has used these forums to discuss scientific progress, regulatory plans such as orphan drug applications, and timelines related to moving HemaXellerate into or through Phase I clinical trials.

For holders and prospective investors in RGBPP, these public presentations and SEC filings provide insight into the company’s development priorities, regulatory interactions, and financing activities. Because Regen BioPharma’s programs are at pre‑clinical and early clinical stages, outcomes depend on scientific, clinical, and regulatory factors that are inherently uncertain.